Novel transcript, antisense to CLVS1

ENSG00000293914 is annotated as a "novel transcript, antisense to CLVS1" in genome databases, meaning it is a non-coding RNA transcript situated on the opposite (antisense) strand relative to the CLVS1 gene. There is no strong evidence that this antisense transcript encodes a protein or serves as a recognized therapeutic target such as a receptor, enzyme, transporter, or transcription factor. It does not have a canonical full name beyond its description and does not appear in disease, drug, or biomarker databases. It is not the same as CLVS1 (clavesin 1), which is a protein-coding gene involved in lysosome organization and disease processes[1][2][4]. No therapeutic or biomarker roles are documented for this antisense RNA. Therefore, this entry does not correspond to a conventional drug target, and there is not enough information to treat it as such. The request likely references a misclassification or noncanonical "target". Key Points: - ENSG00000293914 denotes a *novel, uncharacterized non-coding antisense transcript* relative to the CLVS1 locus, not a classical therapeutic target. - There is *no evidence* supporting its current or potential use as a target or biomarker in any therapeutic area. - If a canonical therapeutic gene target was intended, it is likely the CLVS1 gene (clavesin 1, ENSG00000177182), not its antisense transcript, and the request may be based on incorrect or overly broad target selection[1][2][4].

Other names

ENSG00000293914